Oncology development

What an Early-Onset Colorectal Cancer Tumor Atlas Means for Trial Design

A Nature Medicine atlas found more stromal tissue in younger patients’ microsatellite-stable colorectal tumors. See what future trials can test and how sites can prepare.

By Lampgen Clinical Research

Gloved hands hold an illustrated pathology slide beside the title “From tumor atlas to trial design.” The study profiled 189 colorectal tumors, including 54 diagnosed before age 50.
AI-generated editorial illustration of a pathology slide for Lampgen Clinical Insights.

3 min read · estimated

Sources
189 tumors profiled54 diagnosed before age 50
Primary colorectal tumors from patients across eight decades of life

What the source reported

A tumor atlas published in Nature Medicine found that younger patients with microsatellite-stable (MSS) colorectal cancer had a higher proportion of stromal cells in their tumors. Stromal cells help form and support the tissue in and around a tumor. The finding gives researchers a way to investigate whether that tissue environment helps explain variation in clinical outcomes. An observational atlas cannot establish how a patient will respond to a therapy. [1, 2]

Porter and colleagues used single-nucleus RNA sequencing to profile gene activity in 189 primary tumors from patients aged 29 to 90 and older. The set included 54 tumors diagnosed before age 50 and 135 diagnosed at age 50 or older. The team analyzed age across the full range as well as using the under-50 cutoff. It accounted for factors including tumor location, stage, sex and treatment before surgery in its main analyses. [1, 3]

The researchers confirmed the difference in cell composition using tissue imaging in a separate cohort of 712 MSS tumors. Only 18 of those tumors came from patients diagnosed before age 50. They also found higher activity of some long noncoding RNAs and, in left-sided MSS tumors, stronger inferred signaling linked to epithelial-to-mesenchymal transition, a process by which cells can acquire characteristics associated with movement and invasion. Those signaling results came from a smaller subset and need functional validation. The atlas lacked matched normal tissue, and age and tumor location are difficult to disentangle. [1–3]

The American Cancer Society reports that U.S. colorectal cancer incidence among people under 50 increased 2.9% annually from 2013 through 2022. The atlas characterizes the tumors after diagnosis. The causes of the rise in incidence and the clinical value of these molecular findings remain open questions. [1, 4]

What this means for trial teams

Plan the comparison before enrollment. A follow-up study could prespecify an analysis of age as a continuous variable alongside the under-50 comparison, then check whether the signal persists in patients with similar tumor location, stage and microsatellite status. A link with outcomes would help establish whether the signal is prognostic. Showing that it predicts greater benefit from a specific treatment requires a design that compares treatment effects across biomarker groups.

Track how each specimen becomes usable data. A sponsor can agree with pathology and its central lab on which tissue is required, when it must be collected, how it travels and what qualifies it for analysis. Build consent, block retrieval, processing times, shipment, receipt and assay results into one reconciliation process. Review how many specimens reach each step and why others drop out. NCI’s biospecimen best practices provide a reference for collection, processing and quality controls. [5]

Check who is represented in the final analysis. Compare enrollment, specimen availability and assay success by age group and site type, with safeguards for small groups. When feasible, include community practices, align collections with routine visits and check whether extra appointments or specimen transfers create barriers. If younger adults or patients at community sites are less likely to contribute usable tissue, the study team can locate the point of loss and consider how it affects interpretation. [6]

At Lampgen Clinical Research, we assess oncology CRA fit against the work a protocol requires. For a specimen-intensive study, ask candidates how they would reconcile a missing pathology block, document an out-of-window collection and escalate recurring assay failures. Those decisions help the trial team account for whose tissue reached the analysis.

Sources

  1. Porter et al. | Nature Medicine original study
  2. Nature Medicine | Research briefing
  3. Dana-Farber Cancer Institute | Cohort, methods and interpretation
  4. American Cancer Society | U.S. colorectal cancer statistics
  5. National Cancer Institute | Best Practices for Biospecimen Resources
  6. Lampgen Clinical Insights | Participation burden and patient access

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?